Erratum: Antibody validation (BioTechniques (2010) 48, (197-209) DOI: 10.2144/000113382);Antibody validation

BioTechniques

Volumn 48, Issue 3, 2010, Pages 197-209

  Bordeaux, Jennifer ^a   Welsh, Allison W ^a   Agarwal, Seema ^a   Killiam, Elizabeth ^a   Baquero, Maria T ^a   Hanna, Jason A ^a   Anagnostou, Valsamo K ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Immunofluorescence; Immunohistochemistry; Validation

Indexed keywords

ANTIBODY; REAGENT; TUMOR MARKER;

ACCURACY; ALGORITHM; ANALYTIC METHOD; ANTIBODY SPECIFICITY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRACTICE GUIDELINE; PROGNOSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TISSUE SECTION; VALIDATION PROCESS; VALIDITY;

EID: 77954062372     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000113382     Document Type: Erratum

References (42)

1. Dowsett, M., W.M. Hanna, M. Kockx, F. Penault-Llorca, J. Rüschoff, T. Gutjahr, K. Habben, and M.J. van de Vijver. 2007. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod. Pathol. 20:584-591.
2. Goldstein, N.S., S.M. Hewitt, C.R. Taylor, H. Yaziji, D.G. Hicks, and Members of the Ad-Hoc Committee on Immunohistochemistry Standardization. 2007. Recommendations for improved standardization of immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 15:124-133.
3. Shi, S.-R., C. Liu, and C.R. Taylor. 2007. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J. Histochem. Cytochem. 55:105-109.
4. Wolff, A.C., M.E.H. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Allred, R.J. Cote, M. Dowsett, P.L. Fitzgibbons, et al. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25:118-145.
5. Hicks, D.G. and S. Kulkarni. 2008. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129:263-273.
6. Yaziji, H., C.R. Taylor, N.S. Goldstein, D.J. Dabbs, E.H. Hammond, B. Hewlett, A.D. Floyd, T.S. Barry, et al. 2008. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 16:513-520.
7. Deutsch, E.W., C.A. Ball, J.J. Berman, G.S. Bova, A. Brazma, R.E. Bumgarner, D. Campbell, H.C. Causton, et al. 2008. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat. Biotechnol. 26:305-312.
8. McShane, L.M., D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark. 2006. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 100:229-235. (Pubitemid 44631925)
9. Mullett, W.M., E.P. Lai, and J.M. Yeung. 2000. Surface plasmon resonance-based immunoassays. Methods 22:77-91.
10. Franklin, M.C., K.D. Carey, F.F. Vajdos, D.J. Leahy, A.M. de Vos, and M.X. Sliwkowski. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328.
11. Hsi, E.D. 2001. A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Arch. Pathol. Lab. Med. 125:289-294.
12. Leong, A.S. 2004. Quantitation in immuno histology: fact or fiction? A discussion of variables that influence results. Appl. Immunohistochem. Mol. Morphol. 12:1-7.
13. Michel, M.C., T. Wieland, and G. Tsujimoto. 2009. How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch. Pharmacol. 379:385-388.
14. Jositsch, G., T. Papadakis, R.V. Haberberger, M. Wolff, J. Wess, and W. Kummer. 2009. Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 379:389-395.
15. Jensen, B.C., P.M. Swigart, and P.C. Simpson. 2009. Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch. Pharmacol. 379:409-412.
16. Ramos-Vara, J.A. 2005. Technical aspects of immunohistochemistry. Vet. Pathol. 42:405-426.
17. Willingham, M.C. 1999. Conditional epitopes. is your antibody always specific? J. Histochem. Cytochem. 47:1233-1236.
18. Saper, C.B. and P.E. Sawchenko. 2003. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J. Comp. Neurol. 465:161-163.
19. Pezzella, F., A.G. Tse, J.L. Cordell, K.A. Pulford, K.C. Gatter, and D.Y. Mason. 1990. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am. J. Pathol. 137:225-232.
20. Willingham, M.C. and K. Bhalla. 1994. Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J. Histochem. Cytochem. 42:441-450.
21. Jacobs, T.W., A.M. Gown, H. Yaziji, M.J. Barnes, and S.J. Schnitt. 1999. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 17:1983-1987.
22. Spicer, S.S., M.A. Spivey, M. Ito, and B.A. Schulte. 1994. Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells. J. Histochem. Cytochem. 42:213-221.
23. Pozner-Moulis, S., M. Cregger, R.L. Camp, and D.L. Rimm. 2007. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab. Invest. 87:251-260.
24. Grimsey, N.L., C.E. Goodfellow, E.L. Scotter, M.J. Dowie, M. Glass, and E.S. Graham. 2008. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J. Neurosci. Methods 171:78-86.
25. Major, S.M., S. Nishizuka, D. Morita, R. Rowland, M. Sunshine, U. Shankavaram, F. Washburn, D. Asin, et al. 2006. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics 7:192.
26. Björling, E. and M. Uhlén. 2008. Antibodypedia, a portal for sharing antibody and antigen validation data. Mol. Cell. Proteomics 7:2028-2037.
27. Skliris, G.P., B.G. Rowan, M. Al-Dhaheri, C. Williams, S. Troup, S. Begic, M. Parisien, P.H. Watson, and L.C. Murphy. 2009. Immunohistochemical validation of multiple phosphospecific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res. Treat. 118:443-453.
28. Sompuram, S.R., V. Kodela, K. Zhang, H. Ramanathan, G. Radcliffe, P. Falb, and S.A. Bogen. 2002. A novel quality control slide for quantitative immunohistochemistry testing. J. Histochem. Cytochem. 50:1425-1434.
29. Saper, C.B. 2005. An open letter to our readers on the use of antibodies. J. Comp. Neurol. 493:477-478.
30. Gustavson, M.D., B. Bourke-Martin, D. Reilly, M. Cregger, C. Williams, J. Mayotte, M. Zerkowski, G. Tedeschi, et al. 2009. Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis. Arch. Pathol. Lab. Med. 133:1413-1419.
31. van der Vegt, B., G.H. de Bock, J. Bart, N.G. Zwartjes, and J. Wesseling. 2009. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod. Pathol. 22:879-886.
32. Zafrani, B., M.H. Aubriot, E. Mouret, P. De Crémoux, Y. De Rycke, A. Nicolas, E. Boudou, A. Vincent-Salomon, et al. 2000. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37:536-545. (Pubitemid 32099165)
33. Sasano, H., T.J. Anderson, S.G. Silverberg, R.J. Santen, M. Conway, D.P. Edwards, A. Krause, A.S. Bhatnagar, et al. 2005. The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer. J. Steroid Biochem. Mol. Biol. 95:35-39.
34. Cheang, M.C., D.O. Treaba, C.H. Speers, I.A. Olivotto, C.D. Bajdik, S.K. Chia, L.C. Goldstein, K.A. Gelmon, et al. 2006. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J. Clin. Oncol. 24:5637-5644.
35. Brock, J.E., J.L. Hornick, A.L. Richardson, D.A. Dillon, and S.C. Lester. 2009. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. Am. J. Clin. Pathol. 132:396-401.
36. Couchman, J.R. 2009. Commercial antibodies: the good, bad, and really ugly. J. Histochem. Cytochem. 57:7-8.
37. Mandell, J.W. 2003. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am. J. Pathol. 163:1687-1698.
38. Mandel l, J.W. 2008. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem. Cell Biol. 130:465-471.
39. Camp, R.L., V. Neumeister, and D.L. Rimm. 2008. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26:5630-5637.
40. Kay, E., A. O'Grady, J.M. Morgan, S. Wozniak, and B. Jasani. 2004. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J. Clin. Pathol. 57:1140-1144.
41. Rhodes, K.J. and J.S. Trimmer. 2008. Antibody-based validation of CNS ion channel drug targets. J. Gen. Physiol. 131:407-413.
42. Kalyuzhny, A.E. 2009. The dark side of the immunohistochemical moon: industry. J. Histochem. Cytochem. 57:1099-1101.